Health Care Lobbying and Oncology.

IF 14.8 2区医学 Q1 ONCOLOGY

Journal of the National Comprehensive Cancer Network Pub Date : 2024-04-19 DOI:10.6004/jnccn.2023.7120

Nirmal Choradia, Aaron Mitchell, Ryan Nipp

{"title":"Health Care Lobbying and Oncology.","authors":"Nirmal Choradia, Aaron Mitchell, Ryan Nipp","doi":"10.6004/jnccn.2023.7120","DOIUrl":null,"url":null,"abstract":"Background: The health care industry spends more on lobbying than any other industry, with more than $700 million spent in 2022. However, health care lobbying related to cancer has not been characterized. In this study, we sought to describe overall health sector lobbying spending and oncology-related lobbying spending across patient and clinician organizations.Methods: We obtained lobbying data from OpenSecrets.org and the Federal Election Commission. Overall health sector lobbying spending was categorized by OpenSecrets into 4 groups: pharmaceuticals/health products, health services/health maintenance organizations (HMOs), hospitals/nursing homes, and health professionals. We then identified and categorized 4 oncology-related lobbying groups: oncology physician professional organizations (OPPOs), prospective payment system (PPS)-exempt cancer hospitals, patient advocacy organizations, and provider networks (eg, US Oncology Network). We described temporal trends in lobbying spending from 2014 to 2022, in both overall dollar value (inflation-adjusted 2023 dollars) and in per-physician spending (using American Association of Medical Colleges [AAMC] data for number of hematologists/oncologists) using a Mann-Kendall trend test.Results: Among the overall health sector lobbying, pharmaceuticals/health products had the greatest increase in lobbying spending, with an increase from $294 million in 2014 to >$376 million in 2022 (P=.0006). In contrast, lobbying spending by health professionals did not change, remaining at $96 million (P=.35). Regarding oncology-related lobbying, OPPOs and PPS-exempt cancer hospitals had a significant increase of 170% (P=.016) and 62% (P=.009), respectively. Per-physician spending also demonstrated an increase from $60 to $134 for OPPOs and from $168 to $226 for PPS-exempt cancer hospitals. Overall, OPPO lobbying increased as a percentage of overall physician lobbying from 1.16% in 2014 to 3.76% in 2022.Conclusions: Although overall health sector lobbying has increased, physician/health professional lobbying has remained relatively stable in recent years, spending for lobbying by OPPOs has increased. Continued efforts to understand the utility and value of lobbying in health care and across oncology are needed as the costs of care continue to increase.","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":" ","pages":"226-230"},"PeriodicalIF":14.8000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2023.7120","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The health care industry spends more on lobbying than any other industry, with more than $700 million spent in 2022. However, health care lobbying related to cancer has not been characterized. In this study, we sought to describe overall health sector lobbying spending and oncology-related lobbying spending across patient and clinician organizations.

Methods: We obtained lobbying data from OpenSecrets.org and the Federal Election Commission. Overall health sector lobbying spending was categorized by OpenSecrets into 4 groups: pharmaceuticals/health products, health services/health maintenance organizations (HMOs), hospitals/nursing homes, and health professionals. We then identified and categorized 4 oncology-related lobbying groups: oncology physician professional organizations (OPPOs), prospective payment system (PPS)-exempt cancer hospitals, patient advocacy organizations, and provider networks (eg, US Oncology Network). We described temporal trends in lobbying spending from 2014 to 2022, in both overall dollar value (inflation-adjusted 2023 dollars) and in per-physician spending (using American Association of Medical Colleges [AAMC] data for number of hematologists/oncologists) using a Mann-Kendall trend test.

Results: Among the overall health sector lobbying, pharmaceuticals/health products had the greatest increase in lobbying spending, with an increase from $294 million in 2014 to >$376 million in 2022 (P=.0006). In contrast, lobbying spending by health professionals did not change, remaining at $96 million (P=.35). Regarding oncology-related lobbying, OPPOs and PPS-exempt cancer hospitals had a significant increase of 170% (P=.016) and 62% (P=.009), respectively. Per-physician spending also demonstrated an increase from $60 to $134 for OPPOs and from $168 to $226 for PPS-exempt cancer hospitals. Overall, OPPO lobbying increased as a percentage of overall physician lobbying from 1.16% in 2014 to 3.76% in 2022.

Conclusions: Although overall health sector lobbying has increased, physician/health professional lobbying has remained relatively stable in recent years, spending for lobbying by OPPOs has increased. Continued efforts to understand the utility and value of lobbying in health care and across oncology are needed as the costs of care continue to increase.

查看原文本刊更多论文

医疗游说与肿瘤学。

背景：医疗保健行业在游说方面的花费高于其他任何行业，2022 年的花费超过 7 亿美元。然而，与癌症相关的医疗游说活动还没有被描述出来。在本研究中，我们试图描述卫生部门的总体游说支出以及患者和临床医生组织的肿瘤相关游说支出：我们从 OpenSecrets.org 和联邦选举委员会获得了游说数据。OpenSecrets 将卫生部门的总体游说支出分为 4 组：药品/保健产品、医疗服务/健康维护组织 (HMO)、医院/疗养院和卫生专业人员。然后，我们对 4 个与肿瘤相关的游说团体进行了识别和分类：肿瘤医生专业组织 (OPPO)、预期支付系统 (PPS) 豁免癌症医院、患者权益组织和医疗服务提供者网络（如美国肿瘤网络）。我们使用 Mann-Kendall 趋势检验法描述了 2014 年至 2022 年间游说支出的时间趋势，包括总体美元价值（经通胀调整后的 2023 年美元）和每位医生的支出（使用美国医学院协会 [AAMC] 有关血液病学家/肿瘤学家人数的数据）：在整个卫生部门的游说活动中，药品/保健品的游说支出增幅最大，从 2014 年的 2.94 亿美元增至 2022 年的 3.76 亿美元（P=.0006）。相比之下，卫生专业人员的游说支出没有变化，仍为 9600 万美元（P=.35）。在与肿瘤相关的游说方面，OPPO 和 PPS 豁免癌症医院分别大幅增加了 170% (P=.016) 和 62% (P=.009)。OPPO 的每名医生支出也从 60 美元增至 134 美元，而 PPS 豁免癌症医院的每名医生支出则从 168 美元增至 226 美元。总体而言，OPPO 的游说活动占整体医生游说活动的比例从 2014 年的 1.16% 增加到 2022 年的 3.76%：虽然卫生部门的整体游说活动有所增加，但近年来医生/卫生专业人员的游说活动保持相对稳定，OPPO 的游说支出有所增加。随着医疗成本的不断增加，需要继续努力了解游说在医疗保健和肿瘤学领域的作用和价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the National Comprehensive Cancer Network ONCOLOGY-

CiteScore

20.20

自引率

0.00%

发文量

388

审稿时长

4-8 weeks

期刊介绍： JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care. Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.